Overview

Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF

Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that patients with Spondylarthropathies in remission under antiTNF therapy, can maintain the remission with a maintenance dose inferior to the currently recommended dose schedule.
Phase:
Phase 4
Details
Lead Sponsor:
Spanish Clinical Pharmacology Society
Collaborator:
Spanish reumatology Society
Treatments:
Adalimumab
Antibodies, Monoclonal
Etanercept
Golimumab
Infliximab